ConvaTec Group’s (CTEC) “Buy” Rating Reaffirmed at Jefferies Financial Group

Jefferies Financial Group reissued their buy rating on shares of ConvaTec Group (LON:CTEC) in a research report released on Friday morning, Marketbeat.com reports. Jefferies Financial Group currently has a GBX 325 price target on the stock.

Other research analysts have also issued research reports about the stock. Stifel Nicolaus restated a “buy” rating and issued a GBX 315 price target on shares of ConvaTec Group in a research report on Wednesday, March 11th. Citigroup reiterated an “outperform” rating and set a GBX 315 price objective on shares of ConvaTec Group in a research report on Thursday, March 5th. Berenberg Bank reissued a “buy” rating and set a GBX 340 price objective on shares of ConvaTec Group in a research note on Tuesday, April 21st. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a GBX 315 target price on shares of ConvaTec Group in a report on Wednesday, April 8th. Nine investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of GBX 319.67.

ConvaTec Group Stock Performance

Shares of CTEC opened at GBX 208.40 on Friday. The company has a debt-to-equity ratio of 106.19, a current ratio of 1.53 and a quick ratio of 0.96. The firm’s 50 day moving average is GBX 224.16 and its 200-day moving average is GBX 231.89. ConvaTec Group has a 12-month low of GBX 199 and a 12-month high of GBX 311.20. The stock has a market capitalization of £4.07 billion, a P/E ratio of 24.23, a P/E/G ratio of 0.93 and a beta of 0.78.

Insider Activity at ConvaTec Group

In related news, insider Jonny Mason sold 291,149 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of GBX 234, for a total value of £681,288.66. Company insiders own 0.95% of the company’s stock.

About ConvaTec Group

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.